Mucositis News and Research

RSS
FDA approves new drug and chemotherapy combination for treatment of adult patients with AML

FDA approves new drug and chemotherapy combination for treatment of adult patients with AML

Stivarga receives expanded FDA approval for treatment of liver cancer

Stivarga receives expanded FDA approval for treatment of liver cancer

FDA approves new maintenance therapy for recurrent cancers

FDA approves new maintenance therapy for recurrent cancers

FDA approves new therapy for initial treatment of soft tissue sarcoma

FDA approves new therapy for initial treatment of soft tissue sarcoma

IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

SciClone plans to pursue development of SGX942 in the Greater China market

SciClone plans to pursue development of SGX942 in the Greater China market

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Emergent BioSolutions sign development agreement

Alternating sunitinib, everolimus not supported in advanced RCC

Alternating sunitinib, everolimus not supported in advanced RCC